Helicase A-Binding Protein 95 kDa: A Promising Drug Target and Biomarker

Target Name: AKAP8L

NCBI ID: G26993

AKAP8L

Helicase A-Binding Protein 95 kDa: A Promising Drug Target and Biomarker

Helicase A-binding protein 95 kDa (AKAP8L) is a protein that is expressed in various cell types, including neurons, muscle cells, and red blood cells. It is a member of the Helicase family of proteins, which are involved in the processing and transport of various molecules, including proteins, nucleic acids, and small molecules. The function of AKAP8L is to regulate the activity of other proteins, particularly those involved in the delivery of nucleic acids to the cytoplasm.

Despite its importance in various cellular processes,AKAP8L is not well understood, and its functions are not fully known. However, research has identified several potential drug targets and biomarkers associated with AKAP8L. In this article, we will explore the potential of AKAP8L as a drug target and biomarker, and discuss the current research on its biology and potential clinical applications.

Drug Target Potential

AKAP8L has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The protein is composed of 94 amino acid residues and has a calculated pI of 9.67. It consists of a catalytic active site, a transmembrane region, and an N-terminus region that is involved in its interactions with other proteins.

The catalytic active site of AKAP8L contains a unique Rossmann-fold, which is a structural motif that is involved in the formation of protein-protein bonds. This motif is known to be involved in protein-ligation and has been implicated in various cellular processes, including DNA replication, transcription, and translation.

In addition to its catalytic active site, AKAP8L has been shown to interact with several protein partners, including the transcription factor, p53. This interaction between AKAP8L and p53 suggests that the protein may play a role in the regulation of gene expression and may be a potential drug target for cancer.

Biomarker Potential

AKAP8L has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein is expressed in various tissues and has been shown to be involved in the delivery of nucleic acids to the cytoplasm, which may be a potential biomarker for neurodegenerative diseases.

In addition to its involvement in neurodegenerative diseases, AKAP8L has also been shown to be involved in cancer. The protein has been shown to play a role in the regulation of apoptosis, which is a process that is involved in the elimination of damaged cells. This suggests that AKAP8L may be involved in the regulation of cancer cell survival and may be a potential biomarker for cancer.

Current Research

Several studies have investigated the functions of AKAP8L, with a focus on its potential as a drug target and biomarker. These studies have identified the protein's catalytic active site as a potential target for small molecules, including inhibitors that can modulate its activity. In addition, studies have shown that AKAP8L interacts with several protein partners, including the transcription factor, p53, and have suggested that the protein may play a role in the regulation of gene expression and protein synthesis.

Conclusion

In conclusion, AKAP8L is a protein that has not yet been fully understood, but has potential as a drug target and biomarker. Its unique structure and involvement in various cellular processes make it an attractive target for small molecules, and its potential as a biomarker for cancer and neurodegenerative diseases make it a promising protein for future research. Further studies are needed to fully understand the functions of AKAP8L and its potential as a drug

Protein Name: A-kinase Anchoring Protein 8 Like

Functions: Could play a role in constitutive transport element (CTE)-mediated gene expression by association with DHX9. Increases CTE-dependent nuclear unspliced mRNA export (PubMed:10748171, PubMed:11402034). Proposed to target PRKACA to the nucleus but does not seem to be implicated in the binding of regulatory subunit II of PKA (PubMed:10761695, PubMed:11884601). May be involved in nuclear envelope breakdown and chromatin condensation. May be involved in anchoring nuclear membranes to chromatin in interphase and in releasing membranes from chromating at mitosis (PubMed:11034899). May regulate the initiation phase of DNA replication when associated with TMPO isoform Beta (PubMed:12538639). Required for cell cycle G2/M transition and histone deacetylation during mitosis. In mitotic cells recruits HDAC3 to the vicinity of chromatin leading to deacetylation and subsequent phosphorylation at 'Ser-10' of histone H3; in this function seems to act redundantly with AKAP8 (PubMed:16980585). May be involved in regulation of pre-mRNA splicing (PubMed:17594903)

The "AKAP8L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKAP8L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets